



Date: 14th November, 2024

To
The Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001.

Dear Sir/Madam,

Sub: Submission of Un-Audited Financial Results under regulation 30 and 33 of SEBI (LODR) Regulations, 2015.

Scrip Code: 524636 | Scrip Symbol: OXYGENTAPH

This is to inform you that the Board of Directors of the Company at its meeting held on this day i.e., 14th November, 2024 has, inter alia, approved Un-Audited Financial Results for the Second Quarter ended on 30th September, 2024 as recommended by the Audit Committee and reviewed by the Statutory Auditors.

Further please find enclosed herewith the following documents in terms of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015:

1. Un-Audited financial results for the Second Quarter and Half Year ended on 30th September, 2024.
2. Un- Audited Statement of Assets and Liabilities of the Company for the Second Quarter and Half year ended on 30th September, 2024.
3. Un- Audited Cash flow Statement of the Company for the Second Quarter and Half year ended on 30th September, 2024.
4. Limited Review Report on Un-Audited financial results for the second quarter and half year ended on 30th September, 2024 issued by the Statutory Auditors of the Company.

The meeting commenced at 03.00 P.M. and concluded at 06.30 P.M.

This is for your information and necessary records.
Thanking you,

Yours faithfully,
For **Oxygenta Pharmaceutical Limited**

Sai Sudhakar Vankineni
Managing Director
DIN: 00733001

OXYGENTA PHARMACEUTICAL LIMITED

CIN : L24110TG1990PLC012038

Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State

Corp Office: Plot no: 43, Sy no. 55 to 58, The Park View 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500032

Website: www.oxygentapharma.com, Email Ids: md@oxygentapharma.com, cs@oxygentapharma.com, Phone Number: 040- 23355938

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2024

| S. No | Particulars | (Rupees in Lakhs except for EPS) | | | | | |
|--------------|--|----------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------------------|
| | | QUARTER ENDED | | | HALF YEAR ENDED | | YEAR ENDED |
| | | 30-09-2024 (Unaudited) | 30-06-2024 (Unaudited) | 30-09-2023 (Unaudited) | 30-09-2024 (Unaudited) | 30-09-2023 (Unaudited) | 31-03-2024 (Audited) |
| 1 | Income from Operations | | | | | | |
| (a) | Net Sales/Income from Operations (net of excise duty) | 1,400.52 | 1,262.08 | 1,307.59 | 2,662.60 | 1,993.98 | 3,964.21 |
| (b) | Other Operating Income | 74.93 | 2.25 | 0.12 | 77.18 | 0.12 | 4.24 |
| | Total income from operations (net) | 1,475.45 | 1,264.33 | 1,307.71 | 2,739.78 | 1,994.10 | 3,968.45 |
| 2 | Expenses | | | | | | |
| (a) | Cost of materials consumed | 793.67 | 1,065.78 | 1,167.65 | 1,859.45 | 1,976.45 | 3,505.52 |
| (b) | Purchase of stock-in-trade | - | - | - | - | - | - |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 290.39 | (65.90) | (13.69) | 224.49 | (120.76) | (152.68) |
| (d) | Direct Manufacturing Expenses | 255.56 | 195.22 | 298.64 | 450.78 | 592.96 | 743.85 |
| (e) | Employee benefit expense | 139.50 | 148.18 | 32.59 | 287.68 | 50.39 | 599.37 |
| (f) | Finance Costs | 69.09 | 40.68 | 34.10 | 109.77 | 63.51 | 159.39 |
| (g) | Depreciation and amortisation expense | 65.99 | 64.94 | 83.40 | 130.93 | 133.40 | 266.07 |
| (h) | Other expenses | 138.59 | 97.12 | 20.00 | 235.71 | 56.11 | 237.80 |
| | Total expenses | 1,752.79 | 1,546.03 | 1,622.68 | 3,298.81 | 2,752.05 | 5,359.32 |
| 3 | Profit from operations before other income and exceptional items (1-2) | (277.34) | (281.70) | (314.97) | (559.03) | (757.95) | (1,390.87) |
| 4 | Other income | - | - | - | - | - | - |
| 5 | Profit from ordinary activities before exceptional items (3+4) | (277.34) | (281.70) | (314.97) | (559.03) | (757.95) | (1,390.87) |
| 6 | Exceptional (expenses)/income | - | - | (3.02) | - | (15.91) | 3.70 |
| 7 | Profit / (Loss) from ordinary activities before tax (7+ 8) | (277.34) | (281.70) | (317.99) | (559.03) | (773.86) | (1,387.17) |
| 8 | Tax (expense)/credit | - | - | - | - | - | - |
| | Current Tax | - | - | - | - | - | - |
| | Deferred Tax | 8.05 | (145.37) | (1.99) | (137.32) | (1.99) | (1,039.24) |
| 9 | Net Profit / (Loss) from ordinary activities after tax | (285.39) | (136.33) | (316.00) | (421.71) | (771.87) | (347.93) |
| 10 | Extraordinary items (net of tax expense) | - | - | - | - | - | - |
| 11 | Net Profit / (Loss) for the period (11+ 12) | (285.39) | (136.33) | (316.00) | (421.71) | (771.87) | (347.93) |
| 12 | Other Comprehensive Income | - | - | - | - | - | 7.11 |
| 13 | Total Comprehensive Income | (285.39) | (136.33) | (316.00) | (421.71) | (771.87) | (340.82) |
| 14 | Share of Profit/(loss) of associates | - | - | - | - | - | - |
| 15 | Minority interest | - | - | - | - | - | - |
| 16 | Paid-up equity share capital (face value Rs. 10/-) | 3,548.35 | 3,548.35 | 3,348.35 | 3,548.35 | 3,348.35 | 3,348.35 |
| 17.i | Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised): | | | | | | |
| (a) | Basic | (0.81) | (0.39) | (0.87) | (1.20) | (2.52) | (1.09) |
| (b) | Diluted | (0.78) | (0.37) | (0.76) | (1.15) | (2.41) | (1.04) |
| 17.ii | Earnings per share (after extraordinary items) (of Rs.10/- each) (not annualised): | | | | | | |
| (a) | Basic | (0.81) | (0.39) | (0.87) | (1.20) | (2.52) | (1.09) |
| (b) | Diluted | (0.78) | (0.37) | (0.76) | (1.15) | (2.41) | (1.04) |

NOTES:

- The above results have been reviewed by the Audit committee and approved by the Board of Directors at its meeting held on 14th November, 2024 at Corporate office, Plot no: 43, Sy no. 55 to 58, The Park View 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500032.
- The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules, 2016.
- The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products, Hence, segmental reporting as per IND AS-108 is not made.
- Total Turnover for the current quarter reported Rs 1400.52 Lakhs compared to Rs.1307.59 for the corresponding quarter of the previous year.
- The Loss before tax for the current quarter is Rs.277.34 Lakhs compared to Loss Before tax of Rs.317.99 Lakhs for the corresponding quarter of the previous year.
- Previous period/year figures have been regrouped and rearranged wherever necessary to facilitate comparison.
- During the quarter, the Company has made a provision for doubtful debts amounting to ₹116.90 lakhs. This provision has been established to account for receivables that may not be fully recoverable, reflecting a prudent approach to financial risk management. By setting aside this amount, the Company aims to safeguard its financial position and ensure transparency in reporting.

- 9 The Company received a demand notice under Section 14-B of the Employees' Provident Fund and Miscellaneous Provisions Act, 1952, on November 9, 2022, requiring payment of dues related to employee provident fund obligations. In response, the Company filed a writ petition before the Hon'ble High Court, seeking relief from the demand. However, on August 19, 2024, the Court dismissed the writ petition, advising the Company to settle the outstanding liability. Following the Court's directive, the Company has acknowledged and accepted the liability, recording an amount of ₹27.01 lakhs in its books of accounts to reflect this obligation.
- 10 During the previous years, the Company made a payment of ₹41.93 lakhs. However, it has come to light that no interest has been accrued on this amount during the current quarter. This situation is not fully aligned with the requirements outlined in Section 186 of the Companies Act, 2013. The Company is reviewing this matter to ensure future compliance and alignment with statutory obligations.
- 11 The Company is actively working to complete the identification of its MSME creditors, though a few gaps remain in this process. To facilitate accurate identification, we have requested all suppliers to submit self-declaration forms confirming their MSME status. The Company is currently in the process of collecting these declarations from suppliers to enhance accuracy in reporting. Additionally, the Company has yet to implement a bill-to-bill adjustment process, which has posed challenges in preparing a precise aging schedule for its creditors. Addressing these outstanding issues remains a priority, and the Company is committed to achieving full compliance and transparency in its reporting.
- 12 On April 26, 2023, the Company issued a total of 12,837,200 share warrants on a preferential basis. As of the second quarter, 1,500,000 share warrants remained pending for conversion. These pending warrants, which were required to be converted into equity shares by October 26, 2024, were successfully converted within the stipulated timeframe in October. This conversion into equity shares was completed in compliance with regulatory requirements.

Date: 14/11/2024
Place, Hyderabad



For and on behalf of the Board of Directors
OXYGENTA PHARMACEUTICAL LIMITED

Sai Sudhakar

SAI SUDHAKAR VANKINENI
Managing Director
DIN :00733001

OXYGENTA PHARMACEUTICAL LIMITED
CIN: L24110TG1990PLC012038

Statement of Assets and Liabilities as at September 30, 2024

(All amounts are in INR Lakhs, except for share data and where otherwise)

| Particulars | Note | As at September, 2024 | As at March 31, 2024 |
|--|------|-----------------------|----------------------|
| I. ASSETS | | | |
| Non-current assets | | | |
| (a) Property, plant and equipment | 3 | 2,982.82 | 2,935.84 |
| (b) Other intangible assets | | - | - |
| (c) Capital work in progress | | - | - |
| (d) Goodwill | | - | - |
| (e) Right-of-use assets | | - | - |
| (f) Financial assets | | - | - |
| (i) Investments | 4A | 4.94 | 4.94 |
| (ii) Loans | 4B | 41.94 | 41.94 |
| (iii) Trade Receivables | | - | - |
| (iv) Other financial assets | 5 | 52.47 | 52.61 |
| (g) Deferred tax assets (net) | 6 | 1,010.62 | 873.30 |
| (h) Other non-current assets | | - | - |
| Total non-current assets | | 4,092.78 | 3,908.62 |
| Current assets | | | |
| Inventories | 7 | 1,409.13 | 1,371.65 |
| (a) Financial assets | | | |
| (i) Trade receivables | 8 | 1,516.14 | 736.06 |
| (ii) Cash and cash equivalents | 9 | 0.19 | 0.17 |
| (iii) Bank balances other than Cash and cash equivalents | | 9.91 | 9.91 |
| (iv) Other financial assets | | - | - |
| (b) Other current assets | 10 | 297.26 | 292.80 |
| Total current assets | | 3,232.62 | 2,410.59 |
| TOTAL ASSETS | | 7,325.41 | 6,319.22 |
| II. EQUITY AND LIABILITIES | | | |
| Equity | | | |
| (a) Equity share capital | 11 | 3,548.35 | 3,348.35 |
| (b) Other equity | 12 | -5,662.30 | -5,360.59 |
| Total equity | | -2,113.95 | -2,012.24 |
| Non-current liabilities | | | |
| (a) Financial liabilities | | | |
| (i) Borrowings | 13A | 5,089.71 | 4,900.17 |
| (ii) Lease liabilities | | - | - |
| (b) Provisions | 14A | 63.94 | 61.78 |
| (c) Deferred Tax Liabilities | | - | - |
| Total non-current Liabilities | | 5,153.65 | 4,961.95 |
| Current liabilities | | | |
| (a) Financial liabilities | | | |
| (i) Borrowings | 13B | 971.50 | 823.20 |
| (ii) Lease liabilities | | - | - |
| (iii) Trade payables | 15 | - | - |
| (a) Total outstanding dues of micro and small enterprises | | 517.66 | 330.78 |
| (b) Total outstanding dues of creditors other than micro and small enterprises | | 2,465.95 | 1,957.95 |
| (iii) Other financial liabilities | | - | - |
| (b) Other current liabilities | 16 | 303.62 | 250.41 |
| (c) Provisions | 14B | 27.00 | 7.16 |
| Total current liabilities | | 4,285.71 | 3,369.51 |
| TOTAL EQUITY AND LIABILITIES | | 7,325.41 | 6,319.21 |

The accompanying notes form an integral part of the financial

for and on behalf of the Board of Directors of
OXYGENTA PHARMACEUTICAL LIMITED
CIN: L24110TG1990PLC012038



V Sai Sudhakar
Dr V Sai Sudhakar
Managing Director & CFO

OXYGENTA PHARMACEUTICAL LIMITED

Statement of Cash Flows for the Period ended September 30, 2024

(All amounts are in INR Lakhs, except for share data and where otherwise stated)

| Particulars | Period ended September 30, 2024 | Year ended March 31, 2024 |
|--|------------------------------------|------------------------------|
| I CASH FLOW FROM OPERATING ACTIVITIES | | |
| Profit before exceptional item and tax | (559.03) | (1,387.17) |
| Adjustments for: | | |
| Depreciation and amortisation expenses | 130.93 | 266.07 |
| Finance costs | 109.77 | 159.39 |
| Interest income | (2.25) | (1.78) |
| Provision for bad and doubtful debts | - | - |
| Forex Loss/ (gain) | 3.53 | (1.35) |
| Provision for gratuity and leave encashment | - | 8.46 |
| Operating profit before working capital changes | (317.04) | (956.37) |
| Working capital changes: | | |
| (Increase)/Decrease in Trade receivables | (783.60) | 319.58 |
| (Increase) in Other financial assets | 0.14 | - |
| Decrease in Other current assets | (4.46) | 10.72 |
| (Increase)/Decrease in Inventories | (37.48) | (201.14) |
| (Increase)/Decrease in Other non current assets | - | (4.65) |
| (Decrease) in Trade payables | 694.86 | (395.72) |
| Increase/(Decrease) in Other current liabilities | 53.21 | - |
| Increase/(Decrease) in Other financial liabilities | - | (80.18) |
| (Decrease) in Provisions | 22.00 | 2.80 |
| Cash generated from operations | (372.37) | (1,304.96) |
| Income taxes received/(paid) | - | - |
| Net cash generated from operating activities | (372.37) | (1,304.96) |
| II CASH FLOW FROM INVESTING ACTIVITIES | | |
| Payment for property plant and equipment and CWIP | (177.91) | (410.57) |
| Interest received on fixed deposits | 2.25 | 1.78 |
| Movement in other bank balances and bank deposits with maturity period of more than three months | - | - |
| Net cash generated from/(used in) investing activities | (175.67) | (408.78) |
| III CASH FLOW FROM FINANCING ACTIVITIES | | |
| Interest paid | (109.77) | (159.39) |
| Repayment of lease liabilities | - | - |
| Proceeds from issuing shares | 200.00 | 2,892.33 |
| Proceeds from issuing other equity instruments | 120.00 | 56.25 |
| Increase/(decrease) from Long term borrowings | 189.54 | (1,075.98) |
| Increase/(decrease) from Short term borrowings | 148.30 | - |
| Net cash generated from/(used in) financing activities | 548.06 | 1,713.20 |
| IV Net increase in cash and cash equivalents | 0.02 | (0.54) |
| Cash and cash equivalents at the beginning of the year | 10.08 | 10.62 |
| Cash and cash equivalents at the end of the year (refer note 11) | 10.10 | 10.08 |

The accompanying notes form an integral part of the financial statements

for and on behalf of the Board of Directors of



OXYGENTA PHARMACEUTICAL LIMITED
CIN: L24110TG1990PLC012038


Dr V Sai Sudhakar
Dr V Sai Sudhakar
Managing Director & CFO



Independent Auditor's Review Report on Unaudited Quarterly Financial Results of OXYGENTA PHARMACEUTICAL LIMITED Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Oxygenta Pharmaceutical Limited.

1. We have reviewed the accompanying statement of unaudited financial results of Oxygenta Pharmaceutical Limited ("the Company") for the quarter ended and Six months ended September 30, 2024 ("the Statement ") attached herewith, being submitted by the company Pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Regulation")
2. This Statement, which is the responsibility of the company's Management and approved by the Board of Directors, has been Prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting", prescribed under Section 133 of the companies act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard of Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review Consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to




obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit Opinion.

4. Based on our review conducted and Procedures performed as stated in Paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited Financial results prepared in accordance with the recognition and measurement principles laid down in IND AS 34, Prescribed under Section 133 of the Companies act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A.M REDDY & D.R REDDY

Chartered Accountants

Firms Registration No: 009068S



D. Rama Krishna Reddy
Partner



Membership No. 209211

UDIN: 24209211BKHHUA1353

Place: Hyderabad

Date: November 14, 2024